Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Number of shares composing the share capital
Theoretical number of voting rights
30th June 2020
* including 2,155,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on Novembre 19th 2019.
Euronext Growth Paris
ALPHA/FR – Reuters: ALPHA.PA
First day of cotation
18 July 2016
Number of shares
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Eligible to PEA-PME (French fiscal advantage)
Explore the latest Pharnext press releases
Find the full recording of Pharnext’s virtual R&D Day: unmet need in Charcot-Marie-Tooth Disease Type 1A, potential for PXT3003, interest of our Pleotherapy platform.
Pharnext will attend joint meeting of the Associazione Italiana per lo studio del Sistema Nervoso Periferico and the Associazione Italiana di Miologia
Presentation of the R&D Day Event
Letter to shareholders
Want to join our team?
46 Rue Saint-Lazare
75009 Paris, France
+33 (0)1 41 09 22 email@example.com